NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis → Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed! (From Priority Gold) (Ad) Free ADIL Stock Alerts $1.57 +0.03 (+1.95%) (As of 09:44 AM ET) Add Compare Share Share Today's Range$1.53▼$1.6150-Day Range$1.13▼$3.2652-Week Range$0.77▼$14.00Volume17,477 shsAverage Volume4.57 million shsMarket Capitalization$6.36 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Adial Pharmaceuticals alerts: Email Address Ad Priority GoldRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Get your free information kit NOW, before it’s too late. Inside you’ll get the 3 secret strategies you can put in place starting today, so “they” don’t get your money tomorrow.Click here for your free guide About Adial Pharmaceuticals Stock (NASDAQ:ADIL)Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder. The company also focuses on developing drug candidates for non-opioid pain reduction and other diseases and disorders. Adial Pharmaceuticals, Inc. was founded in 2010 and is based in Charlottesville, Virginia.Read More ADIL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADIL Stock News HeadlinesApril 24, 2024 | uk.investing.comAdial Pharmaceuticals secures new addiction treatment patentApril 22, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeMay 8, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 22, 2024 | benzinga.comEXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US PatentApril 22, 2024 | globenewswire.comAdial Pharmaceuticals Granted Key Patent from the United States Patent and Trademark OfficeApril 11, 2024 | msn.comWhy Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars TodayApril 11, 2024 | msn.comDow Falls Over 1%; US Inflation Rate Accelerates In MarchApril 10, 2024 | marketwatch.comAdial Pharmaceuticals Shares Rise 78% After Positive Trial Data for AD04May 8, 2024 | Gold Safe Exchange (Ad)Gold Set to EXPLODE!Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.April 10, 2024 | msn.comAdial stock rallies 81% on data for alcohol abuse drugApril 10, 2024 | investorplace.comWhy Is Adial Pharmaceuticals (ADIL) Stock Up 59% Today?April 10, 2024 | msn.comEXCLUSIVE: Adial Pharmaceuticals' Potential Treatment For Alcohol Use Disorder Shows Encouraging Safety, Patient ComplianceApril 10, 2024 | finance.yahoo.comAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderApril 10, 2024 | globenewswire.comAdial Pharmaceuticals Announces Peer-Reviewed Publication Highlighting Promising Safety Data and High Patient Compliance in a Clinical Trial of AD04 as a Potential Treatment for Alcohol Use DisorderApril 2, 2024 | globenewswire.comAdial Pharmaceuticals Reports 2023 Fiscal Year Financial Results and Provides Business UpdateMarch 19, 2024 | investing.comAdial Pharmaceuticals Inc (ADIL)March 16, 2024 | finance.yahoo.comMASI Apr 2024 120.000 callMarch 16, 2024 | finance.yahoo.comMASI Apr 2024 125.000 putMarch 11, 2024 | benzinga.comPeering Into Adial Pharmaceuticals's Recent Short InterestMarch 1, 2024 | globenewswire.comAdial Pharmaceuticals Announces Exercise of Warrants for $3.5 Million Gross ProceedsMarch 1, 2024 | investing.comAdial Pharmaceuticals secures new patent for AD04 drugFebruary 28, 2024 | msn.comWhy Adial Pharmaceuticals Stock Is Blasting OffFebruary 28, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc: Adial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeFebruary 28, 2024 | finance.yahoo.comEXCLUSIVE: Adial Pharmaceuticals Secures New US Patent Covering Lead Product For Alcohol Use DisorderFebruary 28, 2024 | globenewswire.comAdial Pharmaceuticals Awarded New Patent from the United States Patent and Trademark OfficeFebruary 15, 2024 | finanznachrichten.deAdial Pharmaceuticals, Inc.: Adial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20February 15, 2024 | finance.yahoo.comAdial Pharmaceuticals to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20See More Headlines Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/11/2021Today5/08/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ADIL CUSIPN/A CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees4Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($5.72) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-5,120,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-250.52% Return on Assets-183.24% Debt Debt-to-Equity RatioN/A Current Ratio4.90 Quick Ratio4.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.46 per share Price / Book0.63Miscellaneous Outstanding Shares4,050,000Free Float3,468,000Market Cap$6.24 million OptionableNo Data Beta1.41 Beginners Guide To Retirement StocksClick the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report Key ExecutivesMr. Cary John Claiborne MBA (Age 63)CEO, President & Director Comp: $728.31kDr. Bankole A. Johnson DSc (Age 64)FRCPsych, M.D., M.Phil, Ph.D., Founder & Chief Medical Officer Comp: $435kMr. Joseph A. M. Truluck M.B.A. (Age 46)MBA, CFO, Treasurer & Secretary Comp: $358.49kMr. Tony Goodman (Age 60)COO & Director Comp: $33kMr. John R. Martin J.D.Chief Legal OfficerMs. Catherine FratilaControllerMore ExecutivesKey CompetitorsYumanity TherapeuticsNASDAQ:YMTXLixte BiotechnologyNASDAQ:LIXTOragenicsNYSE:OGENKintara TherapeuticsNASDAQ:KTRAEnveric BiosciencesNASDAQ:ENVBView All CompetitorsInsiders & InstitutionsArmistice Capital LLCBought 159,000 shares on 2/13/2024Ownership: 9.578%Kevin SchuylerBought 700 shares on 9/29/2023Total: $1,918.00 ($2.74/share)View All Insider TransactionsView All Institutional Transactions ADIL Stock Analysis - Frequently Asked Questions How have ADIL shares performed in 2024? Adial Pharmaceuticals' stock was trading at $1.86 on January 1st, 2024. Since then, ADIL shares have decreased by 17.2% and is now trading at $1.54. View the best growth stocks for 2024 here. Are investors shorting Adial Pharmaceuticals? Adial Pharmaceuticals saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 1,010,000 shares, an increase of 11,509.2% from the March 31st total of 8,700 shares. Based on an average daily volume of 6,220,000 shares, the short-interest ratio is presently 0.2 days. Currently, 26.7% of the shares of the stock are short sold. View Adial Pharmaceuticals' Short Interest. When is Adial Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our ADIL earnings forecast. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) announced its earnings results on Wednesday, August, 11th. The company reported ($6.25) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($5.00) by $1.25. When did Adial Pharmaceuticals' stock split? Shares of Adial Pharmaceuticals reverse split on Monday, August 7th 2023. The 1-25 reverse split was announced on Monday, August 7th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, August 7th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Adial Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Global Partners (GLP), Corbus Pharmaceuticals (CRBP), Aytu BioPharma (AYTU), T2 Biosystems (TTOO), AIM ImmunoTech (AIM), Tandem Diabetes Care (TNDM), vTv Therapeutics (VTVT), Acasti Pharma (ACST) and Adamis Pharmaceuticals (ADMP). When did Adial Pharmaceuticals IPO? Adial Pharmaceuticals (ADIL) raised $8 million in an initial public offering on Friday, July 27th 2018. The company issued 1,500,000 shares at a price of $5.00 per share. Joseph Gunnar & Co. acted as the underwriter for the IPO and Dawson James Securities was co-manager. Who are Adial Pharmaceuticals' major shareholders? Adial Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional investors include Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include James W Jr Newman, Kevin Schuyler and William B Stilley III. View institutional ownership trends. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ADIL) was last updated on 5/8/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsGold Set to EXPLODE!Gold Safe ExchangeShocking: One AI startup's revenue could surge 4,735%Manward PressThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorAI “wealth window” is closing June 25thParadigm PressElon Musk Secret Crypto Plot ExposedCrypto 101 MediaThe #1 lithium battery stock to have on your radar in 2024!Smallcaps DailyREAD THIS – If You Missed Out On The AI BoomBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.